Rapport Therapeutics (RAPP) Common Equity (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Common Equity of $471.5 million for Q1 2026, up 64.96% year-over-year from $285.8 million in Q1 2025, and down 2.71% quarter-over-quarter from $484.7 million in Q4 2025.
Rapport Therapeutics (RAPP) Common Equity (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Common Equity for 4 consecutive years, with $471.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 64.96% year-over-year to $471.5 million; the TTM figure through Mar 2026 stood at $471.5 million (up 64.96% YoY), while the FY2025 annual figure was $484.7 million, up 58.68% from the prior year.
- Common Equity eased to $471.5 million in Q1 2026 per RAPP's latest filing, from $484.7 million in the prior quarter.
- Across five years, Common Equity topped out at $511.6 million in Q3 2025 and bottomed at -$39.6 million in Q1 2024.
- Historically, Common Equity has averaged $241.2 million across 4 years, with a median of $295.6 million in 2024.
- Annual changes were most pronounced in 2024 — Common Equity surged 3671.36% — and 2025, when it retreated 21.78%.
- Rapport Therapeutics' Common Equity stood at -$25.6 million in 2023, then soared by 1291.49% to $305.4 million in 2024, then soared by 58.68% to $484.7 million in 2025, then decreased by 2.71% to $471.5 million in 2026.
- Business Quant data shows RAPP's Common Equity at $471.5 million in Q1 2026, $484.7 million in Q4 2025, and $511.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 422.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 422.93 Mn |
| Mar 31, 2026 | 471.51 Mn |
| Dec 31, 2025 | 484.65 Mn |
| Sep 30, 2025 | 511.62 Mn |
| Jun 30, 2025 | 263.51 Mn |
| Mar 31, 2025 | 285.84 Mn |
| Dec 31, 2024 | 305.43 Mn |
| Sep 30, 2024 | 323.11 Mn |
| Jun 30, 2024 | 336.89 Mn |
| Mar 31, 2024 | -39.63 Mn |
| Dec 31, 2023 | -25.63 Mn |
| Sep 30, 2023 | -13.12 Mn |
| Jun 30, 2023 | -9.43 Mn |